Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million
HANGZHOU, China, March 29, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a year-on-year increase of 48.3%, and achieved a net profit exceeding USD 14 million, marking its first full-year profitability....
LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%
SHENZHEN, China, March 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the "Group") announced the audited consolidated results for the year ended 31 December 2024 (the "Reporting Period"). ...
tHIS ASEAN 2025 to Showcase Cutting-Edge Medical Technologies and Vast Market Potential of South Asia
Co-located with APHM Conference & Exhibition, the Event Brings Together 200+ Exhibitors and 5,000+ Industry Professionals KUALA LUMPUR, Malaysia, March 28, 2025 /PRNewswire/ -- The Health Industry Series (tHIS ASEAN) 2025, one of the biggest medical and healthcare exhibitions in the ASEAN region, will take place from June 9 to 11 at the Kuala Lumpur Convention Centre in...
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024
HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30,...
Viva Biotech’s Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration ("FDA"), and received the EIR (Establishment Inspection Report) from the FDA. This is the fourth time that Langhua Pharmaceutical has undergone...
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau
SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is...
Fangzhou Inc. Named Among Guangzhou’s Top AI Innovators for Intelligent Healthcare Platform
GUANGZHOU, China, March 28, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as "Most Promising Enterprise," while its H2H Smart Healthcare Ecosystem secured a spot on the "Application Scenario Innovation List" as...
Neutech Group Limited Announces 2024 Annual Results
Deepening the Strategic Transformation toward an Ecosystem of Education, Healthcare, Wellness, and Mind Tour, with Synergies Increasingly Materializing HONG KONG, March 28, 2025 /PRNewswire/ -- On the evening of March 27th, 2025, Neutech Group Limited (Stock Code: 9616.HK) announced the annual results of 2024. In 2024, the Group leveraged the "Education + Technology + Services" tri-engine model and pursued integrated development across...
Wai Yuen Tong leads the digitalization of traditional Chinese medicine introducing Hong Kong’s first smart AI constitution analysis device, pioneers Hong Kong into a new era of healthcare in...
HONG KONG, March 28, 2025 /PRNewswire/ -- Wai Yuen Tong (0897.HK), a pioneer in traditional Chinese medicine in Hong Kong, announced that starting today, five core stores located in Percival Street Causeway Bay, Nathan Road Mong Kok, Cameron Road Tsim Sha Tsui, New Town Plaza Sha Tin, and Telford Plaza Kowloon Bay will initiate a trial introduction of the...
Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a Phase 2b study in refractory gout patients with its investigational drug...
